70
Participants
Start Date
March 21, 2019
Primary Completion Date
March 21, 2019
Study Completion Date
March 21, 2019
PQR 309
Intervention of this drug may include safety, tolerability, PK (pharmacokinetics) and efficacy
M.D. Anderson Cancer Center, Houston
Lead Sponsor
Collaborators (1)
Roswell Park Cancer Institute
OTHER
M.D. Anderson Cancer Center
OTHER
Mayo Clinic
OTHER
Hospital Clinic of Barcelona
OTHER
University College London Hospitals
OTHER
Churchill Hospital
OTHER
Case Western Reserve University
OTHER
University Hospital, Zürich
OTHER
PIQUR Therapeutics AG
INDUSTRY